Melanotan II (MT-II) as an Adjunct to NB-UVB Phototherapy for Repigmentation in Stable Nonsegmental Vitiligo
ClinicalTrials.gov · NCT07437560 · Registry updated: 2026-02-27
- Condition / research focus
- NonSegmental Vitiligo; Nonsegmental Vitiligo (Stable)
- Sponsor
- Hudson Biotech
- Countries with listed sites
- China
- Registry dates and results
- Start: 2026-02-02. Completion: 2028-02-17 (may be estimated). No results posted in this registry response.
Products and interventions (3)
Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.
- Melanotan II (MT-II) (drug)
- Placebo (drug)
- Narrowband UV-B (NB-UVB) phototherapy (procedure)
Where the study takes place — 1 listed sites
Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.
- Peking University Shenzhen Hospital
Shenzhen, Guangdong, China
Site recruitment: Recruiting